
Opinion|Videos|December 19, 2023
Future Perspectives and Unmet Needs in HER2+ mCRC Treatment
Drs Ciombor and Ahn discuss emerging HER2-targeted therapies in colorectal cancer, including antibody-drug conjugates and novel antibodies.
Advertisement
Episodes in this series

Advertisement
Related to this article

At the 2026 Chemotherapy Foundation Symposium, Ajai Chari, MD, explained how disease pace and BCMA sequencing guide choosing CAR T or bispecifics.

Amir T. Fathi, MD, discusses where venetoclax/azacitidine fits in fit patients with AML and why a phase 3 trial may be unlikely.

At CFS 2026, Martin Gleave, CM, MD, FRCSC, FACS, explained why higher-volume, high-grade prostate cancer is the sweet spot for perioperative ARPI therapy.

Qingqing Cai, MD, PhD, discussed early efficacy data for rocbrutinib plus R-CHOP in untreated non-GCB DLBCL and how they compare with frontMIND at ESMO 2026.

Ralph V. Boccia, MD, FACP, details the home monitoring tools, prophylaxis, and grade-based approach his practice uses to manage CRS.

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial
2
FDA Approves Neladalkib in Advanced ALK+ Non–Small Cell Lung Cancer
3
FDA Grants Final Approval to Generic Binimetinib in BRAF-Mutant Melanoma, NSCLC
4
IDE849 Gains FDA Alignment on Registrational Trials in Neuroendocrine Carcinomas
5



